Vedanta Biosciences, Inc. Vedanta Biosciences, Inc.

  • Home
  • About
    • Overview
    • Team
    • Scientific Co-Founders and Advisors
    • Board of Directors
  • Pipeline
    • Overview
    • VE303
    • VE202
    • VE800
    • VE707
    • VE416
    • Partnerships
    • Intellectual Property
  • Clinical Trials
    • VE303
    • VE800
    • VE416
    • VE202
    • Expanded Access
  • Platform
    • How Our Drugs Work
    • Discovery Platform
    • Manufacturing Platform
    • Publications
  • News & Media
    • Overview
    • Press Releases
    • In The News
  • Careers
  • Contact
News & Media

News & Media

  • Overview
  • Press Releases
  • In The News

Press Releases

Dec 5, 2019

Vedanta Biosciences Awarded $5.8 Million CARB-X Grant to Accelerate Development of VE707 for Multi-Drug Resistant Infections

Nov 13, 2019

Vedanta Biosciences’ Silvia Caballero, Ph.D., Named to TIME 100 NEXT List for Innovative Leaders

Oct 30, 2019

Vedanta Biosciences CEO Receives 2019 Immigrant Entrepreneur Award

Sep 23, 2019

Vedanta Biosciences Announces $16.6 Million Series C-2 Financing

Jul 1, 2019

Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study

Jun 25, 2019

Vedanta Biosciences’ Silvia Caballero, Ph.D., Named as an MIT Technology Review Global Innovator Under 35

May 13, 2019

Vedanta Biosciences Closes Extended $45.5 Million Series C Financing

May 7, 2019

Vedanta Biosciences Key Microbiome Patent Upheld in European Opposition Proceedings

Jan 23, 2019

Vedanta Biosciences Publishes Seminal Research in Leading Scientific Journal for its Immuno-oncology Candidate, VE800

Dec 24, 2018

Vedanta Biosciences Raises $27 Million Series C Financing to Advance Clinical Pipeline of Microbiome-Derived Product Candidates

  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next »
RSS Feed
© 2023 Vedanta Biosciences, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap